BURTON F. DICKEY, MD

Chair of the Pulmonary Department at the University of Texas M. D. Anderson Cancer Center

Dr. Dickey is a co-founder of Pulmotect and an inventor of the original platform technology. He is an experienced bench investigator with more than 30 years of independent research. He has served on multiple NIH study sections, is an active clinician, participates in several clinical research programs and serves on the advisory board of multiple companies.

SEBASTIAN JOHNSTON, MBBS, PhD, FERS, FRCP, FRSB, FMedSci

Professor of Respiratory Medicine & Allergy at the National Heart and Lung Institute Imperial College London

A world authority and key opinion leader in exacerbations of asthma and COPD, Dr. Johnston has been performing human virus challenge studies in asthma for more than 20 years and is the only investigator worldwide to have performed such studies in people with COPD. With a long and productive history of collaborations with both the pharmaceutical and biotech industry, his work has led to more than 450 research publications and the publishing of 12 patents, and the licensing of these patents to industry. In addition to numerous board member and academic appointments, Dr. Johnston is a UK National Institute of Health Research senior investigator.

Scott E. Evans, MD, FCCP

Associate Professor, Department of Pulmonary Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center

Dr. Evans is a physician-scientist at the University of Texas MD Anderson Cancer Center.  A pulmonary medicine expert with a specialized interest in pneumonia, he runs an NIH-funded laboratory that investigates innate immune responses in the lungs.  Work in Dr Evans’ laboratory lead to the discovery of Pulmotect’s lead compound, PUL-042.  His team remains focused on exploring the mechanisms that underlie inducible resistance, in order to efficiently harness the remarkable protection associated with this phenomenon.

TIM HIGENBOTTAM, DSc, MD, MA, FRCP, FFPM

Vice President Faculty of Pharmaceutical Medicine at Royal College of Physicians London

Tim Higenbottam is a recognized expert in Respiratory Medicine, including asthma, and has extensive experience in clinical development and regulatory affairs from within the pharmaceutical industry and academia. He was Professor of Medicine at Sheffield University from 1995 and 2001. At Chiesi Farmaceutici, he was Director of Corporate Clinical Development and achieved market approvals for the NEXThaler® DPI for Asthma and FOSTAIR® for COPD. Professor Higenbottam previously held senior positions with AstraZeneca.

Steven Rowe, MD, MSPH

Dr. Rowe is a pioneer in the field of personalized therapeutics for cystic fibrosis (CF), cutting-edge discovery in airway disease biology, and translational research in COPD. He is an international authority in the design and conduct of clinical trials targeting the basic CF defect, and has made key advances in the measurement and interpretation of CFTR function in humans and animals. Dr. Rowe co-invented one-micron resolution optical coherence tomography (Micro-OCT) that captures 3D imaging in real-time at the cellular level, and with his collaborators is the first to bring this technique in vivo in humans. Dr. Rowe is Director of the Gregory Fleming Cystic Fibrosis Research Center at UAB, which involves over 100 faculty members and has been continuously funded for over 25 years. He presently has a laboratory of over 25 individuals, embracing lung research from basic discovery, to translational science, to clinical application.

Roy Chemaly, MD, MPH, FACP, FIDSA, CMQ

Dr. Chemaly is a Professor of Medicine in the Department of Infectious Diseases, Infection Control & Employee Health at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Chemaly completed his training in infectious diseases and medical microbiology at the Cleveland Clinic Foundation in Ohio. He is board-certified in internal medicine/infectious diseases, medical quality, and medical microbiology. Dr. Chemaly’s work has been reported in numerous peer-reviewed journals including New England Journal of Medicine, Blood, Journal of Infectious Diseases, and Clinical Infectious Diseases.